The Institute for Clinical and Economic Review (ICER), has posted a draft scoping document that will inform a report on therapies for management of high cholesterol. The report will form the basis of the next public meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC), a core program of ICER. ICER’s report for CEPAC will examine the evidence on the comparative clinical effectiveness and value of drug therapies for managing high cholesterol, including review of the emerging class of drugs for this condition, PCSK9 inhibitors. The scoping document will be open to public comment for one week.
Members of the public are encouraged to submit suggested refinements or additions to the scoping document via email to email@example.com. Comments must be received by 5PM ET on Tuesday, July 14 and must adhere to guidelines as described in the CEPAC public comment guide.
The report will form the basis of the October 27, 2015 CEPAC public meeting, at which the Council will vote on key questions raised in the report, and a policy roundtable will discuss recommendations to apply the evidence to policy and practice.
Additional key dates for the draft report, as well as further information about the October meeting, are included below:
Sept. 8: Draft report and voting questions posted
Sept. 8-Sept. 22: Public comment period on draft report
Oct. 6-Oct. 27: Council reviews revised report
Oct. 27: Public Meeting
Date: October 27, 2015
Location: The Joseph B. Martin Conference Center at Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115
Register to attend the meeting here. Additional meeting details and materials will be posted to the CEPAC website as they become available.